GeneDx Holdings posted a widened net loss of $(12.3) million for the third quarter of 2026, even as it maintained its annual revenue outlook and projected an adjusted net income of approximately $12 million for the full year.
Q3 2026 revenue rose to $123.1M from $116.7M a year earlier and full-year revenue guidance was maintained at $475-490M with adjusted net income quantified at approximately $12 million and adjusted gross margin lifted to approximately 71%. However, exome/genome volume growth guidance was trimmed to at least 28% from at least 30% and exome revenue growth to at least 17% from at least 20%, while the reported net loss widened to $(12.3)M from $(7.6)M and operating cash flow was $(72.0)M. Supportive revenue and profit figures are offset by trimmed growth targets and wider losses.
GeneDx Holdings reported third-quarter 2026 revenue of $123.1 million, up from $116.7 million in the same period last year. Despite maintaining its full-year revenue guidance of $475 to $490 million, the company lowered its growth expectations for exome and genome volumes to at least 28% and revenue to at least 17%.
No, full-year revenue guidance stayed at $475 to $490 million, but volume growth expectations were lowered from at least 30% to at least 28% and exome/genome revenue growth from at least 20% to at least 17%.
On a reported basis it posted a net loss of $(12.3) million, or $(0.41) per share, though adjusted net income was positive at $8.6 million and full-year adjusted net income is guided at approximately $12 million.